Patient Preference Trial for COVID-19 (PPT-COVID)

Coronavirus Clinical Trial

— PPT-COVID  

Official title:

Therapeutic Management in Patients With COVID-19 Infection at Risk of Secondary Aggravation: Patient Preference Trial Comparing Routine Care, Treatment With Hydroxychloroquine or Treatment With Hydroxychloroquine Plus Azithromycin

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04418193
• Other study ID #: 20-08
• Status: Withdrawn
• Start date: April 6, 2020
• Est. completion date: February 4, 2021

Study information

• Verified date: February 2021
• Source: Centre Hospitalier Princesse Grace
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To date no treatment has proven its effectiveness in the caring of patients infected with type 2 Coronavirus. The Centre Hospitalier Princesse Grace (CHPG) has decided to only propose randomized double-blind placebo-controlled clinical trials to patients at the early and symptomatic stages of the disease. Data from the literature show in vitro results on the potential clinical benefit of some treatments such as chloroquine or hydroxychloroquine (HXCQ). Observational data suggest a potential benefit of this treatment alone or in combination with azithromycin (HXCQ + AZ). These data were advertised or led to a request from ambulatory medicine and patients to have access to these treatments despite their poor level of evidence. This leads to a decrease in the number of patients recruitable for clinical trials because they refuse the concept of control arms or they wish active treatment (CQ, HXCQ or HXCQ + AZ) from the start. In this context, we propose to conduct in parallel with randomized trials, a so-called "patient preference" protocol which, after patients information, gives them the choice, either to participate in the trial or to choose between treatment with HXCQ, treatment with HXCQ + AZ or standard of care without medication. The patients follow-up and the main endpoint will be the same under the patient preference protocol as for the randomized trial. The advantage of this approach is to offer a common follow-up to all patients, to take into account patients who refuse to participate in the clinical trial, to obtain external validity data, to reduce selection bias and to increase the heterogeneity of patients exposed to treatment options. The expected objective is to see if the patient preference protocol leads to observe the same effects as in the randomized trial.

Description:

Conduct of the research - Pre-selection / Recruitment It is proposed to participate in the study to patients who cannot or do not wish to participate in a randomized therapeutic trial. - Inclusion procedure During the inclusion visit, if the patient meets the study selection criteria, the investigator delivers oral and written information and responds to any patient questions. - Follow-up of people suitable for research 1. Inclusion visit The treatment chosen by the patient is administered. Socio-demographic, history, clinical and biological data are collected. 2. Visit on day 3 ± 1 Hydroxychloroquinemia is dosed. 3. Visit on day 5 ± 1 A nasopharyngeal swab sample is collected during the routine visit. This sampling is only performed for patients for whom the diagnosis of COVID-19 has been made by RT-PCR. 4. Visit on day 10 ± 1 A nasopharyngeal swab sample is collected during the routine visit. This sampling is only performed for patients for whom the diagnosis of COVID-19 has been made by RT-PCR. Hydroxychloroquinemia is dosed. 5. Visit on day 14 A visit or a telephone call is made to gather the occurrence of clinical events of interest on day 14. The treatments received during the last 14 days are collected. 6. Visit on day 28 A visit or a telephone call is made to gather the occurrence of clinical events of interest on day 28. The treatments received during the last 14 days are collected.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 4, 2021
• Est. primary completion date: February 4, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Adult patients (18+)
• Infection with COVID-19 diagnosed by positive RT-PCR SARS-CoV-2 or, if not performed, by thorax CT-scan suggesting viral pneumonia of peripheral predominance in a clinically significant context.
• Diagnosed within the previous 48 hours.
• Having at least one of the following two risk factors for complications:
• age =75 years old
• Peripheral oxygen saturation (SpO2) = 94% while breathing ambient air, or a partial oxygen pressure (PaO2) to fraction of inspired oxygen (FiO2) ratio = 300 mmHg.
• Patients affiliated with or benefitting from a social security scheme
• Written and signed consent of the patient or a relative or, if not possible, emergency inclusion procedure
• Electrocardiogram showing absence of QT prolongation greater than 440 ms in men and 460 ms in women.
• Patient that can't or don't want to participate to a randomized clinical trial

Exclusion Criteria:

• Age below 18-year of age
• Negative RT-PCR SARS-CoV-2
• Peripheral capillary oxygen saturation less than or equal to 94% (SpO2=94%) despite oxygen therapy greater than or equal to 3 L/min (= 3 L/min)
• Organ failure requiring admission to a resuscitation or high dependency unit
• Comorbidity that is life-threatening in the short-term (life expectancy <3 months)
• Any reason that makes follow-up at day 28 impossible
• Current treatment with hydroxychloroquine or hydroxychloroquine plus azithromycin
• Absolute contraindication to treatment with hydroxychloroquine (known hypersensitivity, concomitant treatment with risk of torsades de pointe) or azithromycin (known hypersensitivity to azithromycin, erythromycin, other macrolide, ketolide, in association with rye ergot alkaloids, cisapride, colchicine or severe hepatic failure)
• glucose-6-phosphate dehydrogenase (G6PD) known deficit
• Porphyria
• Hypokaliemia < 3.5 mmol/L
• Electrocardiogram showing corrected QT prolongation greater than 440 ms in men and 460 ms in women
• Child C liver cirrhosis
• Chronic kidney failure with estimated glomerular filtration rate (GFR) = 30 ml/min
• Pregnant, lactating or parturient women
• Patient included in a randomized clinical trial

Related Conditions & MeSH terms

• Coronavirus
• Coronavirus Infections

Locations

Country	Name	City	State
Monaco	Centre Hospitalier Princesse Grace	Monaco

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Princesse Grace

Country where clinical trial is conducted

Monaco, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.	Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.	day 14
Secondary	Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.	Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.	day 28
Secondary	Clinical evolution on the World Health Organisation (WHO) Ordinal Scale for Clinical Improvement (OSCI) for COVID-19 between day 0 and day 14	Clinical evolution on the World Health Organisation (WHO) Ordinal Scale for Clinical Improvement (OSCI) for COVID-19 between day 0 and day 14. Score is between 0 and 8, 8 being the worst.	day 14
Secondary	Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.	Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28. Score is between 0 and 8, 8 being the worst.	day 28
Secondary	Number of all-cause mortality at day 14	Number of all-cause mortality at day 14	day 14
Secondary	Number of all-cause mortality at day 28	Number of all-cause mortality at day 28	day 28
Secondary	Rate of positive severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) Reverse Transcriptase (RT) - Polymerase Chain Reaction (PCR) on nasopharyngeal samples at day 5	Rate of positive severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2) Reverse Transcriptase (RT) - Polymerase Chain Reaction (PCR) on nasopharyngeal samples at day 5	day 5
Secondary	Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10	Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10	day 10
Secondary	The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.	The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.	day 28
Secondary	Number of all-cause mortality at day 28 in patients aged 75 and older	Number of all-cause mortality at day 28 in patients aged 75 and older	day 28
Secondary	Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older	Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older. Score is between 0 and 8, 8 being the worst.	day 28
Secondary	Rate of severe adverse events at day 28	Rate of severe adverse events at day 28	day 28
Secondary	Number of all-cause mortality at day 14 in patients aged 75 and older	Number of all-cause mortality at day 14 in patients aged 75 and older	day 14